Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Hospitalized COVID-19 (EU SolidAct)
NCT04891133Phase 3Terminated
- Sponsor
- Oslo University Hospital
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 15
01
Overview
A Phase 3 trial of baricitinib in coronavirus disease 2019 (COVID-19), sponsored by Oslo University Hospital. Started Jun 2021; status: terminated.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04891133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891133.